Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

AbbVie : Investigators at AbbVie Detail Findings in Pharmaceutical and Biomedical Analysis (Use of ionic liquids as headspace gas chromatography diluents for...

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 11:53pm CET

Investigators at AbbVie Detail Findings in Pharmaceutical and Biomedical Analysis (Use of ionic liquids as headspace gas chromatography diluents for the analysis of residual solvents in pharmaceuticals)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Biotechnology - Pharmaceutical and Biomedical Analysis. According to news reporting originating in North Chicago, Illinois, by NewsRx journalists, research stated, "In this study, two ionic liquids (ILs), 1-butyl-3-methylimidazolium bis[(trifluoromethyl)sulfonyl]imide ([BMIM][NTf2]) and trihexyltetradecylphosphonium bis[(trifluoromethyl)sulfonyl]imide ([P-66614][NTf2]) were examined as contemporary diluents for residual solvent analysis using static headspace gas chromatography (SHS-GC) coupled with flame ionization detection (FID). ILs are a class of non-molecular solvents featuring negligible vapor pressure and high thermal stabilities."

The news reporters obtained a quote from the research from AbbVie, "Owing to these favorable properties, ILs have potential to enable superior sensitivity and reduced interference, compared to conventional organic diluents, at high headspace incubation temperatures. By employing the [BMIM][NTf2] IL as a diluent, a 25-fold improvement in limit of detection (LOD) was observed with respect to traditional HS-GC diluents, such as N-methylpyrrolidone (NMP). The established IL-based method demonstrated LODs ranging from 5.8 parts-per-million (ppm) to 20 ppm of residual solvents in drug substances. The optimization of headspace extraction conditions was performed prior to method validation. An incubation temperature of 140 degrees C and a 15 min incubation time provided the best sensitivity for the analysis. Under optimized experimental conditions, the mass of residual solvents partitioned in the headspace was higher when using [BMIM][NTf2] than NMP as a diluent. The analytical performance was demonstrated by determining the repeatability, accuracy, and linearity of the method. Linear ranges of up to two orders of magnitude were obtained for class 3 solvents. Excellent analyte recoveries were obtained in the presence of three different active pharmaceutical ingredients."

According to the news reporters, the research concluded: "Owing to its robustness, high throughput, and superior sensitivity, the HS-GC IL-based method can be used as an alternative to existing residual solvent methods."

For more information on this research see: Use of ionic liquids as headspace gas chromatography diluents for the analysis of residual solvents in pharmaceuticals. Journal of Pharmaceutical and Biomedical Analysis, 2017;145():879-886. Journal of Pharmaceutical and Biomedical Analysis can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Pharmaceutical and Biomedical Analysis - www.journals.elsevier.com/journal-of-pharmaceutical-and-biomedical-analysis/)

Our news correspondents report that additional information may be obtained by contacting G.K. Webster, AbbVie Inc, North Chicago, IL 60064, United States. Additional authors for this research include T.D. Ho, J.L. Anderson and O. Nacham (see also Biotechnology - Pharmaceutical and Biomedical Analysis).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.jpba.2017.05.033. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: North Chicago, Illinois, United States, North and Central America, Pharmaceutical and Biomedical Analysis, Biotechnology, AbbVie.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABBVIE
12/13 ABBVIE : Roche boast stellar PhIII leukemia data for a breakthrough combo with b..
12/12 ABBVIE : IMBRUVICA Pooled Analysis Suggests Benefit in Progression-Free Survival..
12/12 ABBVIE : IMBRUVICA Patient-Reported Outcomes Data Detail Long-Term Improvement i..
12/12 ABBVIE : Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetocl..
12/12 ABBVIE : 36 Saudis graduate from AbbVie’s pharma training program
12/11 ABBVIE : IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatme..
12/09 ABBVIE : IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-..
12/09 ABBVIE : IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term ..
12/07 ABBVIE : IMBRUVICA plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenstrom's M..
12/06 ABBVIE : AbbVies IL-23 blocker shows efficacy in psoriasis trial
More news
News from SeekingAlpha
03:17a BIOTECH ANALYSIS CENTRAL PHARMA NEWS : AbbVie And Roche Stellar Data, Aduro Pull..
12/13 ARGENX : This ASH Winner Has Further Upside Ahead
12/13 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 13, 2017
12/13 Why Tech Still Looks So Attractive
12/12 Combination of AbbVie's venetoclax and Rituxan successful in late-stage leuke..
Financials ($)
Sales 2017 27 998 M
EBIT 2017 11 955 M
Net income 2017 7 316 M
Debt 2017 26 790 M
Yield 2017 2,67%
P/E ratio 2017 20,99
P/E ratio 2018 16,55
EV / Sales 2017 6,50x
EV / Sales 2018 5,75x
Capitalization 155 B
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 99,9 $
Spread / Average Target 2,6%
EPS Revisions
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE53.23%155 185
MERCK KGAA-10.38%13 853
CONVATEC GROUP-10.13%5 439